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ABSTRACT
The ARQ 197-215 study randomized patients to tivantinib or placebo and pre-
specified efficacy analyses indicated the predictive value of MET expression as a 
marker of benefit from tivantinib in hepatocellular carcinoma (HCC). We aimed to 
explore the neutrophil-to-lymphocyte ratio (NLR) in 98 ARQ 197-215 patients with 
available absolute neutrophil count and absolute lymphocyte count at baseline. The 
cut-off value used to define high versus low NLR was 3.0. In univariate analysis, 
high NLR was associated with hazard ratio (HR) for overall survival (OS) of 1.58 
[95% confidence interval (CI) 1.01; 2.47; P <0.046], corresponding to median OS 
of 5.1 months versus 7.8 months in patients with low NLR (P = 0.044). In contrast, 
time to progression was not significantly affected by NLR (P = 0.20). Multivariable 
model confirmed that both NLR >3 (P = 0.03) and presence of vascular invasion (P = 
0.017) were negatively associated with OS. After adjustment for vascular invasion, 
NLR independently predicted survival in both the placebo and the tivantinib cohort. 
For OS, no interaction was detected between NLR status and treatment (Pinteraction = 
0.40). Baseline NLR is an independent prognostic biomarker in patients with HCC and 
compensated liver function who are candidate for second-line treatments.
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INTRODUCTION
Hepatocellular carcinoma (HCC) accounts for nearly 
80% of primary liver cancer cases [1] and it is a leading 
cause of death worldwide [2]. Risk stratification in current 
clinical trials for advanced HCC is based on clinical, 
radiologic and biochemical grounds. The underlying 
relationships that link such commonly used variables to 
the degree of liver dysfunction, and possible therapeutic 
interventions, have been further appraised within various 
prognostic systems [3]. 
Among patient-related factors that drive prognosis, 
mounting evidences suggest that cancer-associated 
inflammation is a determinant of disease progression 
and survival in several cancer types, including HCC 
[4, 5]. In particular, the neutrophil-to-lymphocyte ratio 
(NLR), which is hematological surrogate marker of 
the systemic inflammatory response, has gained lot 
of interest in the last decade [6]. The NLR is readily 
evaluable by peripheral blood tests and specifically refers 
to the ratio of the absolute neutrophil count (ANC) to 
absolute lymphocyte count (ALC). In HCC, infiltrating 
neutrophils may affect disease initiation and progression 
acting through immunosuppressive mechanisms, which 
might be mediated either by abnormal chemokine CCL2 
production [7] or increased programmed cell death ligand 
1 expression [8]. Furthermore, neutrophils promote 
angiogenesis in peritumoral stroma of HCC via matrix 
metalloproteinase-9 and vascular endothelial growth 
factor signaling [9]. On the other hand, the densities of 
both tumor-infiltrating T and B lymphocytes were shown 
to be associated with improved survival and decreased 
tumour aggressiveness in HCC patients [10]. Therefore, 
an elevated NLR might mirror an imbalance favoring the 
neutrophil pro-tumorigenic functions at the expenses of 
a decreased anti-tumor immune surveillance of the host. 
These observations are in substantial agreement 
with a recently published meta-analysis showing that a 
low baseline NLR is associated with improved overall 
survival (OS) in HCC patients [11], but the overall 
quality of the studies included, as acknowledged by 
the authors, was low. In addition, heterogeneous tumor 
stages and treatment modalities were considered [11]. 
Finally, arguments supporting the usefulness of the NLR 
in advanced HCC patients receiving medical treatments 
encompass few retrospective series, of which three have 
been published in full-text form [12-14]. 
The ARQ 197-215 was a randomized placebo-
controlled phase II study testing the MET inhibitor 
tivantinib for second-line treatment of HCC patients [15]. 
Although OS was similar in both the tivantinib and the 
placebo arms of the study, a predefined subgroup analysis 
highlighted a significant OS benefit from tivantinib in 
patients with MET-high tumors [15]. 
Given these premises, the current post-hoc analysis 
was performed within the ARQ 197-215 study and aimed 
to further evaluate the prognostic impact of the NLR 
within a prospectively collected, phase II trial dataset 
of patients with advanced HCC and compensated liver 
function who were eligible for second-line treatments.
Beyond those variables usually considered for 
enrollment onto clinical trials, should post-progression 
survival after first-line therapy be influenced by the 
NLR, this would represent a novel criterion worth to be 
considered for the design of future second-line studies in 
HCC.
RESULTS
Patients
A total of 107 patients were enrolled in the ARQ 
197-215 study [15]. Nine patients for whom there were 
no baseline ANC/ALC data were excluded, leaving 
an eligible NLR population of 98 patients. Sixty-five 
patients received tivantinib, and 33 received placebo. 
The prognostic characteristics of patients in the NLR 
population did not substantially differ from those in the 
ARQ 197-215 study. OS in the tivantinib and placebo 
arms was 6.5 and 6.2 months, respectively (P = 0.81), and 
time to progression (TTP) was 1.5 and 1.4 months (P = 
0.223), respectively. In comparison, OS in the tivantinib 
and placebo arms of the ARQ 197-215 population [15] 
was 6.6 and 6.2 months (P = 0.63), while TTP was 1.6 and 
1.4 months (P = 0.04), respectively. 
Baseline NLR and prognostic variables
Table 1 shows baseline characteristics with 
comparisons between the low NLR and high NLR 
groups. When patients were grouped by NLR, there were 
no differences in terms of key baseline characteristics 
including extrahepatic spread, alpha-fetoprotein (AFP) 
levels, MET expression levels, macrovascular invasion, 
treatment arm (tivantinib or placebo). Nevertheless, NLR 
values were found to be directly associated (P <0.001) 
with PLR values.
Association between NLR and outcomes in the 
NLR population
With a median follow up of 18.9 months 
(range 0.6 - 24.8), NLR as a continuous variable was 
inversely associated with OS [Hazard Ratio (HR) 1.19, 
95% confidence interval (CI) 1.07; 1.34; P = 0.002]. 
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Consistently, the association between NLR level and OS 
was confirmed using the median cut-off value of 3.0. The 
median OS values were 5.1 months in patients with NLR 
>3 and 7.8 months in patients with NLR ≤3 (P = 0.044). 
Figure 1 displays the Kaplan-Meier curves for OS for the 
two NLR groups. Compared with the low NLR group, the 
HR for OS in patients with high baseline NLR was 1.58 
(95% CI 1.01; 2.47; P <0.046). 
Also, when the NLR was evaluated as a continuous 
trait, the HR for TTP was 1.07 (95% CI 0.96; 1.19; P = 
0.20). The corresponding median TTP value in both high 
and low NLR groups was 1.4 months (P = 0.10; Figure 2). 
Table 1: Key baseline characteristics and comparisons between the low (≤3) and high (>3) NLR groups.
Group All patients NLR ≤3(N = 49)
NLR >3
(N = 49)
P value
 N % N % N %  
Treatment      
  placebo 33 33.7 18 36.7 15 30.6 0.521
  tivantinib 65 66.7 31 63.3 34 69.4  
Macrovascular invasion      
  No 64 65.3 33 51.6 31 48.4 0.671
  Yes 34 34.7 16 47.1 18 52.9  
Distant metastases      
  No 33 33.7 18 54.5 15 45.5 0.521
  Yes 65 66.3 31 47.7 34 52.3  
Baseline alpha-fetoprotein      
  ≤ median 47 48.0 23 48.9 24 48.9 0.837
  > median 47 48.0 24 51.1 23 51.1  
  missing 4 4.0    
MET expression      
  Low 35 35.7 19 54.3 16 45.7 0.552
  High 36 36.7 17 47.2 19 52,8  
Figure 1: Kaplan–Meier estimates of OS according to NLR levels.
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Long-term survival
There were 22 long-term survivors, defined as 
patients surviving beyond 12 months. Of these, 16 (72.7%) 
had low NLR compared with 6 (27.2%) with high NLR. 
This equated to 32.6% (16 of 49) of all patients with a low 
NLR achieving survival beyond 12 months compared with 
only 12.2% (6 of 49) of all patients with high NLR. The 
Chi-squared test confirmed an association between low 
baseline NLR and long-term survival (P = 0.015).
Multivariable analysis
In univariate analyses, NLR and vascular invasion 
were significantly associated with OS. In contrast, AFP 
median levels, MET expression levels, treatment group, 
and extrahepatic spread were not (data not shown). 
Additionally, using the median cut-off value of 
167, a PLR ≤167 was associated with a median OS of 
9.0 months compared to 4.5 months in patients with PLR 
>167 (HR 1.60, 95% CI 1.02; 2.50, P = 0.040). However, 
due to the strong association with NLR and because 
PLR analyses are beyond the scope of the present study, 
in order to avoid collinearity of single variables and 
redundancy, further analyses were undertaken without 
the PLR. The Cox model confirmed that only NLR and 
vascular invasion independently predicted OS. In this 
model, NLR >3 resulted in poorer survival (HR 1.65; 
95% CI 1.05; 2.59; P = 0.030), as well as macrovascular 
invasion (HR 1.74; 95% CI 1.10; 2.75; P = 0.017). 
Association between NLR and outcomes 
according to treatment arm
In the tivantinib arm, median OS values were 6.5 
months in patients with NLR >3 and 7.6 months in patients 
with NLR ≤3 (P = 0.231). In the placebo arm, median OS 
values were 4.2 months in patients with NLR >3 and 7.9 
months in patients with NLR ≤3 (P = 0.048). Modeling 
NLR as a continuous variable increased the statistical 
significance of the relationship existing between increased 
NLR and risk of death in both tivantinib (HR 1.16, 95% CI 
1.00; 1.30, P = 0.049) and placebo arms (HR 1.30, 95% 
CI 1.08; 1.57, P = 0.006). In other words, these findings 
confirm a concrete risk of death, which gradually increases 
with increasing NLR, but it is not specific to NLR ≤3 
versus >3. In a Cox model, after adjustment for vascular 
invasion, these results remained significant in both 
tivantinib (HR 1.18, 95% CI 1.01; 1.38, P = 0.042) and 
placebo arms (HR 1.32, 95% CI 1.09; 1.61, P = 0.004). 
On the other hand, consistent with results observed in the 
entire NLR population, the associations between NLR 
(either as continuous or categorical variable) and TTP 
within both treatment arms of the trial were not significant 
(data not shown). 
Predictive analyses
Among patients with NLR ≤3, the HR for tivantinib 
effect on OS was 1.2 (95% CI 0.61; 2.38; P = 0.594), 
compared with 0.65 (95% CI 0.34; 1.25; P = 0.199) 
Figure 2: Kaplan–Meier estimates of TTP according to NLR levels.
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in patients with NLR >3. However, the P value for the 
interaction between NLR value and treatment was 0.40, 
thus ruling out a differential effect of tivantinib between 
the two NLR groups. These results confirm that the 
NLR value does not have a predictive role in relation to 
treatment selection. In contrast, also in the current NLR 
population, MET expression confirmed its predictive role 
as a biomarker of tivantinib efficacy in HCC (Pinteraction = 
0.039), as already shown in a previous investigation [16].
Changes in NLR and clinical outcomes
Neutropenia was among the most frequent 
tivantinib-related adverse events, generally occurring 
within the first 30 days of treatment [15]. Included in 
this analysis were patients for which NLR was available 
at D1C1 and at day 1 of cycle 2 (D1C2), which was 
scheduled 28 days after D1C1. Median variation of ANC 
(all-patient cohort) during the first cycle of treatment with 
tivantinib or placebo was -9.0% (range -73.4%; +206.0%). 
In patients receiving tivantinib, the mean variation was 
-11.7% (95% CI -22%; -1.3%) and was statistically 
significantly different from the mean neutrophil variation 
observed in patients receiving placebo (+10.8%, 95% 
CI -8.8%; 30.5%; Pt-test = 0.045). When the neutrophil 
variation was evaluated as a continuous variable, no 
survival differences were observed in univariate analysis 
(P = 0.2), nor after adjustment for treatment assignment 
(P = 0.3). When the two pre-therapy NLR groups (NLR 
≥3 or <3) were further dichotomized according to NLR 
results at D1C2, the four pre-therapy and post-therapy 
NLR groups were: low-low (pre-therapy NLR <3 and 
post-therapy NLR <3) in 31 (38.2%) cases; high-low 
(pre-therapy NLR ≥3 and post-therapy NLR <3) in 12 
(14.8%); high-high (pre-therapy NLR ≥3 and post-therapy 
NLR ≥3) in 29 (35.8%); low-high (pre-therapy NLR <3 
and post-therapy NLR ≥3) in 9 (11.1%). Given the limited 
number of patients experiencing a NLR variation from 
high to low NLR categories or vice versa, and the few 
OS events observed among these patients, further survival 
analyses according to this model were inconclusive (data 
not shown). 
DISCUSSION
In the present study, NLR is an independent 
predictor of OS in a homogeneous cohort of HCC 
patients, having Child-Pugh A or no liver cirrhosis, who 
are candidate for second-line treatment. In such patients, 
the survival differences attributed to NLR status are 
substantial, particularly in light of the survival outcomes 
reported in the ARQ 197-215 study [15]. Furthermore, 
considering the results of the recently reported RESORCE 
trial [17], we believe that in a second-line setting these 
survival differences are of clinical interest. 
The discriminatory effect of NLR was observed 
also within both treatment arms of the ARQ 197-215 
study, namely tivantinib and placebo. Of note, this 
indicate that the prognostic value of NLR is independent 
of a potential key confounder represented by treatment 
allocation. Whereas tivantinib was shown to significantly 
prolong TTP [15], this genuine radiological endpoint did 
not appear to be affected by the NLR. Additionally, the 
survival analysis according to treatment arm suggested 
that the OS benefit deriving from tivantinib over placebo 
could be greater in patients with NLR >3, compared to 
patients with NLR ≤3. However, these results have to be 
cautiously interpreted due to the small number of patients 
considered. Furthermore, the interaction test between NLR 
and treatment did not reach statistical significance. At 
present, MET expression is the only available biomarker 
predicting tivantinib efficacy in advanced HCC [16], and 
these findings remained confirmed even within the slightly 
smaller cohort of patients with available MET results 
considered in the current report. In contrast to a previous 
investigation [18], a high NLR was not associated 
with other negative prognostic factors traditionally 
considered in the setting of advanced HCC, such as 
presence of macrovascular invasion, high AFP levels, or 
extrahepatic metastases. The only remarkable association 
was observed with respect to the PLR, which is another 
marker of systemic inflammatory response. Present data 
on the relationship between PLR and survival in advanced 
HCC are scarce and rather conflicting [13, 19], whereas 
overall data on NLR appear to be more robust. Recently, 
platelets counts, in addition to ANC and ALC, have been 
incorporated within a systemic immune-inflammation 
index (SII) that allowed to discriminate prognosis in a 
retrospective cohort of 56 HCC patients treated with 
sorafenib [14]. Similar findings on the prognostic value of 
the SII were described also in the context of less advanced 
disease stages [20]. It is still unclear which one, between 
SII and NLR, could be the most useful prognosticator in 
advanced HCC.
Interestingly, in small-cell lung cancer it has been 
reported that post-chemotherapy decline of NLR from 
high to low is associated with improved survival [21]. 
Neutropenia was among the most frequent adverse events 
associated with tivantinib [15]. Accordingly, mean ANC 
variations at the end of the first cycle of treatment were 
significantly different in patients receiving tivantinib or 
placebo. However, although 12 patients experienced a 
decline of NLR from high into low category, their OS was 
not significantly different from patients with persistently 
high NLR. 
Our results extend previous retrospective 
observations in the frame of a prospective, placebo-
controlled randomized trial which allows to control for 
potential key confounders. Of note, the NLR can also 
be affected by transient infection or drug treatments, but 
in this study values were recorded in patients with no 
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active infection and prior to the second-line treatment. 
Additionally, blood counts were performed at a central 
lab, thereby minimizing preanalytical/analytical biases 
related to assessments done according to diverse 
instrumental parameters and diverse reference ranges. To 
our knowledge, this report represents one of the largest 
individual analyses evaluating NLR in an advanced/
metastatic HCC population, homogeneous for prior 
treatments and clinical baseline characteristics. 
These are among the main strengths of the current 
investigation. Other determinants of postprogression 
survival have been recently reported in patients with 
compensated liver function who permanently discontinue 
sorafenib, including patterns of radiological progression 
[22] and reasons for sorafenib discontinuation [22, 23]. 
These were not fully acknowledged at the time of the 
ARQ 197-215 protocol writing, and therefore they could 
not be captured in the present analysis. This is a limitation 
inherent to this and other trials where protocols were 
written before these data were published.
A number of cut-off values to categorize NLR have 
been reported in the setting of several cancer types. The 
heterogeneity of such cut-offs could make conclusions 
on the clinical utility of NLR and comparisons between 
studies somehow difficult. However, results of the current 
study overall indicate that the 3.0 cut-off value, which 
is adopted in most studies, is easily reproducible, even 
outside the training sets where it was first generated. 
Clearly, for the development of the NLR as an useful tool 
for prognosis, a consensus needs to be achieved on the 
definitions of ‘high’ versus ‘low’ NLR. 
In conclusion, on the basis of the current study, 
low cost, reproducibility, and easy evaluation of a full 
blood count render the NLR worth of consideration as a 
stratification factor in novel clinical trials for HCC.
Validation of the NLR in the larger, ongoing ARQ 
197-A-U303 study (NCT01755767) is warranted. 
MATERIALS AND METHODS
Patients and trial design
Trial design, eligibility criteria and results of the 
ARQ 197-215 were previously reported [15]. The primary 
objective of the ARQ 197-215 study was to compare 
the effect of tivantinib versus placebo on TTP. Eligible 
patients were enrolled from 23 centers in Italy, Belgium, 
Germany, Canada, and USA. Briefly, they had to have 
Eastern Cooperative Oncology Group performance 
status ≤1, Child-Pugh A or no liver cirrhosis, adequate 
bone marrow, liver, and renal function, histologically or 
cytologically confirmed, unresectable, advanced-stage 
HCC. The eligible population for the current exploratory 
analysis (herein referred to as NLR population) included 
all ARQ 197-215 participants with available white blood 
cell, ANC and ALC data at the day 1 of the first cycle. The 
NLR was calculated using the standard formula: NLR = 
ANC/ALC. Analogously, the platelet-to-lymphocyte ratio 
(PLR) was calculated as a ratio between the absolute 
platelet count to the ALC. Laboratory assessments 
including hematology at day 1 of each treatment cycle 
were performed at a central lab.
Statistical methods
The objective of the present study was to examine 
the relationship between NLR and prognosis. NLR 
was first evaluated as a continuous variable: should a 
statistically significant association be observed, then the 
NLR was categorized. Patients were therefore grouped 
into ‘high’ and ‘low’ NLR populations based upon a cut-
off value of 3.0, which was determined on the basis of 
prior publications in HCC [14] and other solid tumors 
[24]. The 3.0 cut-off also corresponds to the median NLR 
value observed in the current NLR population (range 0.8-
12.8), which can be used in the absence of further clinical 
evidences on a cut-off value to differentiate low and high 
baseline NLR levels. TTP was calculated from the start 
of first-line treatment until disease progression. OS was 
calculated from the start of first-line treatment until death 
or last follow-up. Kaplan-Meier method was used to 
estimate and plot survival curves and differences between 
groups were tested by the log rank test. Variables which 
were statistically significant in the univariate analysis were 
entered into a multivariable Cox proportional hazards 
model to assess the prognostic value of baseline NLR 
taking into account the effect of confounding factors. 
Interaction between treatment group and NLR was 
assessed to verify whether the treatment effect differed 
between the NLR groups. 
Data were summarized as frequencies, proportions 
and differences between groups were tested by the Chi-
squared test for categorical data. Continuous variables 
were described as median and range, the Pearson 
correlation coefficient was used to test for correlation, 
differences between groups were evaluated comparing 
means by the t-test. All analyses were done using the Stata 
version 13 statistical package. P <0.05 was considered 
significant.
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